Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy

Redox Biology

Volumn 6, Issue , 2015, Pages 311-317

  Rapozzi, Valentina ^a   Della Pietra, Emilia ^a   Bonavida, Benjamin ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Molecular pathways.; Nitric oxide; Photodynamic therapy; Resistance; Tumor response

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BREAST CANCER RESISTANCE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTOPORPHYRIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR YY1; NITRIC OXIDE DONOR; PEBP1 PROTEIN, HUMAN; PHOTOSENSITIZING AGENT; TRANSCRIPTION FACTOR; YY1 PROTEIN, HUMAN;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROTECTION; DRUG CYTOTOXICITY; DRUG POTENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; MELANOMA; NONHUMAN; OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN CANCER; TUMOR MICROENVIRONMENT; ANTIBODY SPECIFICITY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIGHT; METABOLISM; NEOPLASMS; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

GASTROPODA;

APOPTOSIS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGHT; NEOPLASMS; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE DONORS; ORGAN SPECIFICITY; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SIGNAL TRANSDUCTION; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; YY1 TRANSCRIPTION FACTOR;

EID: 84940049562     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.07.015     Document Type: Article

References (95)

1. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., Moan J., Peng Q. Photodynamic therapy. J. Natl. Cancer Inst. 1998, 90:889-905.
2. Dolmans D., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3:380-387.
3. Iyer A.K., Greish K., Seki T., Okazaki S., Fang F., Takeshita K., Maeda H. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J. Drug Target 2007, 15:496-506.
4. Kessel D. The role of low-density lipoproteins in the biodistribution of photosensitizing agents. J. Photochem. Photobiol. B 1992, 14:261-266.
5. Sibani S.A., McCarron P.A., Woolfson A.D., Donnelly R.F. Photosensitiser delivery for photodynamic therapy. Part 2: systemic carrier platforms. Expert Opin. Drug Deliv. 2008, 5:1241-1254.
6. Juzeniene A., Nielsen K.P., Moan J. Biophysical aspects of photodynamic therapy. J. Environ. Pathol. Toxicoly Oncol. 2006, 25:7-28.
7. Henderson B.W., Busch T.M., Snyder J.W. Fluence rate as a modulator of PDT mechanisms. Lasers Surg. Med. 2006, 38:489-493.
8. Brancaleon L., Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med. Sci. 2002, 17:173-186.
9. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D., Korbelik M., Moan J., Mroz P., Nowis D., Piette J., Wilson B.C., Golab J. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 2011, 61:250-281.
10. Wilson B.C., Patterson M.S. The physics, biophysics and technology of photodynamic therapy. Phys. Med. Biol. 2008, 53:R61-R109.
11. Plaetzer K., Krammer B., Berlanda J., Berr F., Kiesslich T. Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med. Sci. 2009, 24:259-268.
12. Juzeniene A., Juzenas P., Ma L.W., Iani V., Moan J. Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy. Lasers Med. Sci. 2004, 19:139-149.
13. Allison R.R., Sibata C.H. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagn. Photodyn. Ther. 2010, 7:61-75.
14. Buytaert E., Dewaele M., Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim. Biophys. Acta 2007, 1776:86-107.
15. Castano A.P., Demidova T.N. HamblinMR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagn. Photodyn. Ther. 2004, 1:279-293.
16. Sattler U.G., Mueller-Klieser W. The anti-oxidant capacity of tumour glycolysis. Int. J. Radiat. Biol. 2009, 85:963-971.
17. Golab J., Nowis D., Skrzycki M., Czeczot H., Baranczyk-Kuzma A., Wilczynski G.M., Makowski M., Mroz P., Kozar K., Kaminski R., Jalili A., Kopec' M., Grzela T., Jakobisiak M. Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol - A superoxide dismutase inhibitor. J. Biol. Chem. 2003, 278:407-414.
18. Hanlon J.G., Adams K., Rainbow A.J., Gupta R.S., Singh G. Induction of Hsp60 by photofrin-mediated photodynamic therapy. J. Photochem. Photobiol. B 2001, 64:55-61.
19. Nonaka M., Ikeda H., Inokuchi T. Inhibitory effect of heat shock protein 70 on apoptosis induced by photodynamic therapy in vitro. Photochem. Photobiol. 2004, 79:94-98.
20. Oleinick N.L., Morris R.L., Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem. Photobiol. Sci. 2002, 1:1-21.
21. Dougherty T.J., Kaufman J.E., Goldfarb A., Weishaupt K.R., Boyle D., Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978, 38:2628-2635.
22. Gao F., Bai Y., Ma S.-R., Liu F., Li Z.S. Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J Hepatbiliary-Pancreat. Sci. 2010, 17:125-131.
23. Fayter D., Corbett M., Heirs M., Fox D., Eastwood A. A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol. Assess. 2010, 14:1-288.
24. Córdoba F., Braathen L.R., Weissenberger J., Vallan C., Kato M., Nakashima I., Weis J., von Felbert V. 5-Aminolaevulinic acid photodynamic therapy in a transgenic mouse model of skin melanoma. Exp. Dermatol. 2005, 14:429-437.
25. Nestor M.S., Gold M.H., Kauvar A.N., Taub A.F., Geronemus R.G., Ritvo E.C., Goldman M.P., Gilbert D.J., Richey D.F., Alster T.S., Anderson R.R., Bank D.E., Carruthers A., Carruthers J., Goldberg D.J., Hanke C.W., Lowe N.J., Pariser D.M., Rigel D.S., Robins P., Spencer J.M., Zelickson B.D. The use of photodynamic therapy in dermatology: results of a consensus conference. J. Drugs Dermatol. 2006, 5:140-154.
26. Morton C.A. Methyl aminolevulinate: atinic keratoses and Bowen's disease. Dermatol. Clin. 2007, 25:81-87.
27. Salim A., Leman J.A., McColl J.H., Chapman R., Morton C.A. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br. J. Dermatol. 2003, 148:539-543.
28. Rhodes L.E., de Rie M.A., Leifsdottir R., Yu R.C., Bachmann I., Goulden V., Wong G.A., Richard M.A., Anstey A., Wolf P. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch. Dermatol. 2007, 143:1131-1136.
29. Berroeta L., Clark C., Dawe R.S., Ibbotson S.H., Fleming C.J. A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. Br. J. Dermatol. 2007, 157:401-403.
30. Basset-Seguin N., Bissonnette R., Girard C., Haedersdal M., Lear J.T., Paul C., Piaserico S. Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy. J. Eur. Acad. Dermatol. Venereol. 2014, 28:626-632.
31. Wolfe C.M., Green W.H., Cognetta A.B., Hatfield H.K.A. possible chemopreventive role for photodynamic therapy in Gorlin syndrome: a report of basal cell carcinoma reduction and review of literature. Australas. J. Dermatol. 2013, 54:64-68.
32. Jerjes W., Upile T., Akram S., Hopper C. The Surgical palliation of advanced head and neck cancer using photodynamic therapy. Clin. Oncol. 2010, 22:785-791.
33. D'Cruz A.K., Robinson M.H., Biel M.A. mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients. HeadNeck 2004, 26:232-240.
34. Wolfsen H.C. Carpe luz-seize the light: endoprevention of esophageal adenocarcinoma when using photodynamic therapy with porfimer sodium. Gastrointest. Endosc. 2005, 62:499-503.
35. Nakamura H., Yanai H., Nishikawa J., Okamoto T., Hirano A., Higaki M., Omori K., Yoshida T., Okita K. Experience with photodynamic therapy (endoscopic laser therapy) for the treatment of early gastric cancer. Hepatogastroenterology 2001, 48:1599-1603.
36. Yanai H., Kuroiwa Y., Shimizu N., Matsubara Y., Okamoto T., Hirano A., Nakamura Y., Okita K., Sekine T. The pilot experience of immunotherapy-combined photodynamic therapy for advanced gastric cancer in elderly patients. Int. J. Gastrointest. Cancer 2002, 32:139-142.
37. Witzigmann H., Berr F., Ringel U., Caca K., Uhlmann D., Schoppmeyer K., Tannapfel A., Wittekind C., Mossner J., Hauss J., Wiedmann M. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma - Palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann. Surg. 2006, 244:230-239.
38. Bown S.G., Rogowska A.Z., Whitelaw D.E., Lees W.R., Lovat L.B., Ripley P., Jones L., Wyld P., Gillams A., Hatfield A.W. Photodynamic therapy for cancer of the pancreas. Gut 2002, 50:549-557.
39. Nakamura T., Fukui H., Ishii Y., Ejiri K., Ejiri M. Photodynamic therapy with polypectomy for rectal cancer. Gastrointest. Endosc. 2003, 57:266-269.
40. Abulafi A.M., Dejode M., Allardice J.T., Ansell J., Rogers J., Williams N.S. Adjuvant intraoperative photodynamic therapy in experimental colorectal-cancer. Br. J. Surg. 1995, 82:178-181.
41. Wilson J.J., Jones H., Burock M., Smith D., Fraker D.L., Metz J., Glatstein E., Hahn S.M. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int. J. Oncol. 2004, 24:711-717.
42. Du K.L., Mick R., Busch T.M., Zhu T.C., Finlay J.C., Yu G., Yodh A.G., Malkowicz S.B., Smith D., Whittington R., Stripp D., Hahn S.M. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg. Med. 2006, 38:427-434.
43. Trachtenberg J., Bogaards A., Weersink R.A., Haider M.A., Evans A., McCluskey S.A., Scherz A., Gertner M.R., Yue C., Appu S., Aprikian A., Savard J., Wilson B.C., Elhilali M. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J. Urol. 2007, 178:1974-1979.
44. Trachtenberg J., Weersink R.A., Davidson S.R.H., Haider M.A., Bogaards A., Gertner M.R., Evans A., Scherz A., Savard J., Chin J.L., Wilson B.C., Elhilali M. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 2008, 102:556-562.
45. Berger A.P., Steiner H., Stenzl A., Akkad T., Bartsch G., Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 2003, 61:338-341.
46. Waidelich R., Beyer W., Knuchel R., Stepp H., Baumgartner R., Schroder J., Hofstetter A., Kriegmair M. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology 2003, 61:332-337.
47. Weinberg B.D., Allison R.R., Sibata C., Parent T., Downie G. Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer (NSCLC). Photodiagn. Photodyn. Ther. 2010, 7:50-58.
48. Corti L., Toniolo L., Boso C., Colaut F., Fiore D., Muzzio P.C., Koukourakis M.I., Mazzarotto R., Pignataro M., Loreggian L., Sotti G. Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. Lasers Surg. Med. 2007, 39:394-402.
49. Pass H.I., Temeck B.K., Kranda K., Thomas G., Russo A., Smith P., Friauf W., Steinberg S.M. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann. Surg. Oncol. 1997, 4:628-633.
50. Muller P.J., Wilson B.C. Photodynamic therapy of brain tumors - A work in progress. Lasers Surg. Med. 2006, 38:384-389.
51. Stylli S.S., Kaye A.H., MacGregor L., Howes M., Rajendra P. Photodynamic therapy of high grade glioma-long term survival. J. Clin. Neurosci. 2005, 12:389-398.
52. Quereux G., Brocard A., Saint-Jean M., Peuvrel L., Knol A.C., Allix R., Khammari A., Renaut J.J., Dréno B. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. J. Am. Acad. Dermatol. 2013, 69:890-897.
53. Reiners J.J., Caruso J.A., Mathieu P., Chelladurai B., Yin X.M., Kessel D. Release of cytochrome c and activation of pro-caspase-9 following lysosomal photodamage involves bid cleavage. Cell Death Diff. 2002, 9:934-944.
54. Kessel D. Relocalization of cationic porphyrins during photodynamic therapy. Photochem. Photobiol. Sci. 2002, 1:837-840.
55. Vanlangenakker N., Vanden Berghe T., Krysko D.V., Festjens N., Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr. Mol. Med. 2008, 8:207-220.
56. Zong W.X., Thompson C.B. Necrotic death as a cell fate. Genes Dev. 2006, 20:1-15.
57. Dewaele M., Maes H., Agostinis P. ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy 2010, 6:838-854.
58. Reiners J.J., Agostinis P., Berg K., Oleinick N.L., Kessel D. Assessing autophagy in the context of photodynamic therapy. Autophagy 2010, 6:7-18.
59. Casas A., Di Venosa G., Hasan T., Batlle A. Mechanisms of resistance to photodynamic therapy. Curr. Med. Chem. 2011, 18:2486-2515.
60. B. Bonavida, V. Rapozzi, G. Jori (Eds.) Resistance to Photodynamic Therapy in Cancerof Resistance to Targeted Anti-cancer Therapeutics, vol. 5, Springer, 2015. http://doi:10.1007/978-3-319-12730-9.
61. ACE Moor Signaling pathways in cell death and survival after photodynamic therapy. J. Photochem. Photobiol. B 2000, 57:1-13.
62. Kessel D., Luo Y., Mathieu P., Reiners J.J. Determinants of the apoptotic response to lysosomal photodamage. Photochem. Photobiol. 2000, 71:196-200.
63. Gros P., Ben-Neriah Y., Croop J.M., Housman D.E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986, 323:728-731.
64. Roninson I.B., Chin J.E., Choi K., Gros P., Housman D.E., Fojo A., Shen D.W., Gottesman M.M., Pastan I. Isolation of human MDR-DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:4538-4542.
65. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life Sci. 2008, 65:3145-3167.
66. Doyle L.A., Yang W.D., Abruzzo L.V., Krogmann T., Gao Y.M., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:15665-15670.
67. Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 1998, 58:5337-5339.
68. Busch T.M., Hahn S.M. Multidrug resistance in photodynamic therapy. Cancer Biol. Ther. 2005, 4:195-196.
69. Robey R.W., Steadman K., Polgar O., Bates S.E. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol. Ther. 2005, 4:187-194.
70. Fiel R.J., Dattagupta N., Mark E.H., Howard J.C. Induction of DNA damage by porphyrin photosensitizers. Cancer Res. 1981, 41:3543-3545.
71. Oberdanner C.B., Plaetzer K., Kiesslich T., Krammer B. Photodynamic treatment with fractionated light decreases production of reactive oxygen species and cytotoxicity in vitro via regeneration of glutathione. Photochem. Photobiol. 2005, 81:609-613.
72. Gomer C.J., Ryter S.W., Ferrario A., Rucker N., Wong S., Fisher A,M.R. Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res. 1996, 56:2355-2360.
73. Sikora A.G., Gelbard A., Davies M.A., Sano D., Ekmekcioglu S., Kwon J., Hailemichael Y., Jayaraman P., Myers J.N., Grimm E.A., Overwijk W.W. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin. Cancer Res. 2010, 16:1834-1844.
74. Eyler C.E., Wu Q., Yan K., MacSwords J.M., Chandler-Militello D., Misuraca K.L., Justin D., Lathia J.D., Forrester M.T., Lee J., Stamler J.S., Goldman S.A., Bredel M., McLendon R.E., Sloan A.E., Hjelmeland A.B., Rich J.N. Glioma Stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011, 146:53-66.
75. Rubbo H., Radi R., Trujillo M., Telleri R., Kalyanaraman B., Barnes S., Kirk M., Freeman B.A. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J. Biol. Chem. 1994, 269:26066-26075.
76. Foster M.W., Hess D.T., Stamler J.S. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol. Med. 2009, 15:391-404.
77. Ridnour L.A., Thomas D.D., Donzelli S., Espey M.G., Roberts D.D., Wink D.A., Isenberg J.S. The biphasic nature of nitric oxide responses in tumor biology. Antioxid. Redox Signal. 2006, 8:1329-1337.
78. Thomas D.D., Ridnour L.A., Isenberg J.S., Flores-Santana W., Switzer C.H., Donzelli S., Hussain P., Vecoli C., Paolocci N., Ambs S., Colton C.A., Harris C.C., Roberts D.D., Wink D.A. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic. Biol. Med. 2008, 45:18-31.
79. Wink D.A., Hines H.B., Cheng R.Y., Switzer C.H., Flores-Santana W., Vitek M.P., Ridnour L.A., Colton C.A. Nitric oxide and redox mechanisms in the immune response. J. Leukoc. Biol. 2011, 89:873-891.
80. Burke A.J., Sullivan F.J., Giles F.J., Glynn S.A. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013, 34:503-512.
81. Gupta S., Ahmad N., Mukhtar H. Involvement of nitric oxide during phthalocyanine (Pc4) photodynamic therapy-mediated apoptosis. Cancer Res. 1998, 58:1785-1788.
82. Girotti A.W. Tumor-generated nitric oxide as an antagonist of photodynamic therapy. Photochem. Photobiol. Sci. 2015.
83. Reeves K.J., Reed M.W.R., Brown N.J. Is nitric oxide important in photodynamic therapy?. J Photochem Photobiol B 2009, 95:141-147.
84. Korbelik M., Parkins C.S., Shibuya H., Cecic I., Stratford M.R.L., Chaplin D.J. Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br. J. Cancer 2000, 82:1835-1843.
85. Carneiro Z.A., de Moraes J.C., Rodrigues F.P., de Lima R.G., Curti C., da Rocha Z.N., Paulo M., Bendhack L.M., Tedesco A.C., Formiga A.L., da Silva R.S. Photocytotoxic activity of a nitrosyl phthalocyanine ruthenium complex-a system capable of producing nitric oxide and singlet oxygen. J. Inorg. Biochem. 2011, 105:1035-1043.
86. Giles N.M., Kumari S., Gang B.P., Yuen C.W., Billaud E.M., Giles G.I. The molecular design of S-nitrosothiols as photodynamic agents for controlled nitric oxide release. Chem. Biol. Drug Des. 2012, 80:471-478.
87. Kumari S., Sammut I.A., Giles G.I. The design of nitric oxide donor drugs: s-nitrosothiol tDodSNO is a superior photoactivated donor in comparison to GSNO and SNAP. Eur. J. Pharmacol. 2014, 737:168-176.
88. Rapozzi V., Ragno D., Guerrini A., Ferroni C., Pietra E.D., Cesselli D., Castoria G., Di Donato M., Saracino E., Benfenati V., Varchi G. Androgen receptor targeted conjugate for bimodal photodynamic therapy of prostate cancer in vitro. Bioconjug. Chem. 2015, (Epub ahead of print).
89. Bonavida B., Baritaki S. Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-kappa B/Snail/YY1/RKIP circuitry. Nitric Oxide 2011, 24:1-7.
90. Rapozzi V., Della Pietra E., Zorzet S., Zacchigna M., Bonavida B., Xodo L.E. Nitric oxide-mediated activity in anti-cancer photodynamic therapy. Nitric Oxide 2013, 30:26-35.
91. Della Pietra E., Simonella F., Bonavida B., Xodo L.E., Rapozzi V. Repeated sub-optimal photodynamic treatments with pheophorbide a induce an epithelial mesenchymal transition in prostate cancer cells via nitric oxide. Nitric Oxide 2015, 45:43-53.
92. Yeung K.C., Rose D.W., Dhillon A.S., Yaros D., Gustafsson M., Chatterjee D., McFerran B., Wyche J., Kolch W., Sedivy J.M. Raf kinase inhibitor protein interacts with NF-κB-inducing kinase and TAK1 and inhibits NF-κB activation. Mol. Cell. Biol. 2001, 21:7207-7217.
93. Reynaert N.L., Ckless K., Korn S.H., Vos N., Guala A.S., Wouters E.F., van der Vliet A., Janssen-Heininger Y.M. Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:8945-8950.
94. Rapozzi V., Umezawa K., Xodo L.E. Role of NF-kappaB/Snail/RKIP loop in the response of tumor cells to photodynamic therapy. Lasers Surg. Med. 2011, 43:575-585.
95. Bonavida B., Baritaki S. The novel role of yin yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-κB/snail/YY1/RKIP/PTEN circuitry. Crit. Rev. Oncogenes. 2011, 16:211-226.